Anaconda BioMed, focused on the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS) has appointed Creganna Medical to develop, test and manufacture its ANCD Brain device. Creganna Medical works for the development of minimally invasive devices and now is enrolled in colaboration with Anaconda BioMed in the final stages of development of the neurovascular device for the company's forthcoming clinical trial to obtain CE approval.

"This is another important step for Anaconda Biomed to secure our path to commercialize our 3rd generation thrombectomy device," said the CEO of Anaconda BioMed, Dr. Ofir Arad.

The collaboration between companies is essential for the development of devices that will enhance life expectancy for the patients. Worldwide, AIS affects 15 million people each year, every two seconds somebody undergoes a stroke, and every 10 seconds someone in the world dies from a stroke.

"The ANCD Brain device requires a complex manufacturing process and our expertise in advanced device assembly asures our company will work on the product with high eficiency", said Pat Duane, SVP & GM, Creganna Medical.

More information at prweb

We recommend CataloniaBio's interview to Dr. Marc Ribó, well known neurologist and Anaconda BioMed's cofounder.

Picture: Dr. Ofir Arad and Dr. Marc Ribó, cofounders of Anaconda BioMed -  © Anaconda